Discussant review - EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mo

11 May 2024 (08:00 - 20:00)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Professor Lars Kober

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

9 More presentations in this session

Presentation thumbnail

The effect of empagliflozin after acute myocardial infarction in patients with and without diabetes: a pre-specified analysis of the EMPACT-MI trial

Professor J. Butler (Dallas, US)

Presentation thumbnail

Contemporary guideline-directed medical therapy sequencing and titration in de novo, worsening, and chronic heart failure: first data from the TITRATE-HF study

Professor J. Brugts (Rotterdam, NL)

Presentation thumbnail

Discussant review - The TITRATE-HF study

Professor J. Ezekowitz (Edmonton, CA)

Presentation thumbnail

First implementation results from the Trial for Evaluating Accelerated Guideline-Directed Medical Therapy for Heart Failure

Doctor A. Spahillari (Durham, US)

Presentation thumbnail

Discussant review - TEAM-HF: Implementation Study of Accelerated Heart Failure Guideline-Directed Medical Therapy in a General Cardiology Clinic

Professor J. Celutkiene (Vilnius, LT)

Access the full session

Session thumbnail

Late breaking clinical trials: drugs and disease management

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024

You may be interested in

Congress Presentation

Where do we stand with SGLT2i post-myocardial infarction?

Congress Presentation

Strike early and strong: SGLT2-inhibitors

Congress Session

Late breaking clinical trials: drugs and disease management

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources